227 related articles for article (PubMed ID: 22584871)
1. ALK-mutated non-small-cell lung cancer: a new strategy for cancer treatment.
Cabezón-Gutiérrez L; Khosravi-Shahi P; Diaz-Muñoz-de-la-Espada VM; Carrión-Galindo JR; Eraña-Tomás I; Castro-Otero M
Lung; 2012 Aug; 190(4):381-8. PubMed ID: 22584871
[TBL] [Abstract][Full Text] [Related]
2. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
Doebele RC; Pilling AB; Aisner DL; Kutateladze TG; Le AT; Weickhardt AJ; Kondo KL; Linderman DJ; Heasley LE; Franklin WA; Varella-Garcia M; Camidge DR
Clin Cancer Res; 2012 Mar; 18(5):1472-82. PubMed ID: 22235099
[TBL] [Abstract][Full Text] [Related]
4. Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor.
Won JK; Keam B; Koh J; Cho HJ; Jeon YK; Kim TM; Lee SH; Lee DS; Kim DW; Chung DH
Ann Oncol; 2015 Feb; 26(2):348-54. PubMed ID: 25403583
[TBL] [Abstract][Full Text] [Related]
5. Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report.
Campos-Gomez S; Lara-Guerra H; Routbort MJ; Lu X; Simon GR
Int J Biol Markers; 2015 May; 30(2):e254-7. PubMed ID: 25588859
[TBL] [Abstract][Full Text] [Related]
6. Quantification of Anaplastic Lymphoma Kinase Protein Expression in Non-Small Cell Lung Cancer Tissues from Patients Treated with Crizotinib.
Hembrough T; Liao WL; Hartley CP; Ma PC; Velcheti V; Lanigan C; Thyparambil S; An E; Monga M; Krizman D; Burrows J; Tafe LJ
Clin Chem; 2016 Jan; 62(1):252-61. PubMed ID: 26585927
[TBL] [Abstract][Full Text] [Related]
7. Treatment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race.
de Castro-Carpeño J; Perona R; Belda-Iniesta C
Clin Transl Oncol; 2011 Nov; 13(11):774-9. PubMed ID: 22082640
[TBL] [Abstract][Full Text] [Related]
8. ALK in lung cancer: past, present, and future.
Shaw AT; Engelman JA
J Clin Oncol; 2013 Mar; 31(8):1105-11. PubMed ID: 23401436
[TBL] [Abstract][Full Text] [Related]
9. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.
Cappuzzo F; Moro-Sibilot D; Gautschi O; Boleti E; Felip E; Groen HJ; Germonpré P; Meldgaard P; Arriola E; Steele N; Fox J; Schnell P; Engelsberg A; Wolf J
Lung Cancer; 2015 Feb; 87(2):89-95. PubMed ID: 25576294
[TBL] [Abstract][Full Text] [Related]
10. Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.
Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
Curr Clin Pharmacol; 2016; 11(2):77-87. PubMed ID: 27138017
[TBL] [Abstract][Full Text] [Related]
11. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
Croegaert K; Kolesar JM
Am J Health Syst Pharm; 2015 Sep; 72(17):1456-62. PubMed ID: 26294238
[TBL] [Abstract][Full Text] [Related]
12. Treatment and detection of ALK-rearranged NSCLC.
Peters S; Taron M; Bubendorf L; Blackhall F; Stahel R
Lung Cancer; 2013 Aug; 81(2):145-54. PubMed ID: 23769207
[TBL] [Abstract][Full Text] [Related]
13. Echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-targeted therapy for advanced non-small cell lung cancer: molecular and clinical aspects.
Okamoto I; Nakagawa K
Cancer Sci; 2012 Aug; 103(8):1391-6. PubMed ID: 22568572
[TBL] [Abstract][Full Text] [Related]
14. New strategies for treatment of ALK-rearranged non-small cell lung cancers.
Sasaki T; Jänne PA
Clin Cancer Res; 2011 Dec; 17(23):7213-8. PubMed ID: 22010214
[TBL] [Abstract][Full Text] [Related]
15. Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer.
Camidge DR; Theodoro M; Maxson DA; Skokan M; O'Brien T; Lu X; Doebele RC; Barón AE; Varella-Garcia M
Cancer; 2012 Sep; 118(18):4486-94. PubMed ID: 22282074
[TBL] [Abstract][Full Text] [Related]
16. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
[TBL] [Abstract][Full Text] [Related]
17. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
Shaw AT; Yeap BY; Solomon BJ; Riely GJ; Gainor J; Engelman JA; Shapiro GI; Costa DB; Ou SH; Butaney M; Salgia R; Maki RG; Varella-Garcia M; Doebele RC; Bang YJ; Kulig K; Selaru P; Tang Y; Wilner KD; Kwak EL; Clark JW; Iafrate AJ; Camidge DR
Lancet Oncol; 2011 Oct; 12(11):1004-12. PubMed ID: 21933749
[TBL] [Abstract][Full Text] [Related]
18. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
[TBL] [Abstract][Full Text] [Related]
19. ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.
Casaluce F; Sgambato A; Maione P; Rossi A; Ferrara C; Napolitano A; Palazzolo G; Ciardiello F; Gridelli C
Target Oncol; 2013 Mar; 8(1):55-67. PubMed ID: 23325296
[TBL] [Abstract][Full Text] [Related]
20. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
Kwak EL; Bang YJ; Camidge DR; Shaw AT; Solomon B; Maki RG; Ou SH; Dezube BJ; Jänne PA; Costa DB; Varella-Garcia M; Kim WH; Lynch TJ; Fidias P; Stubbs H; Engelman JA; Sequist LV; Tan W; Gandhi L; Mino-Kenudson M; Wei GC; Shreeve SM; Ratain MJ; Settleman J; Christensen JG; Haber DA; Wilner K; Salgia R; Shapiro GI; Clark JW; Iafrate AJ
N Engl J Med; 2010 Oct; 363(18):1693-703. PubMed ID: 20979469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]